Madison Vaccines, Inc. specializes in developing innovative DNA plasmid immunotherapies for prostate cancer. Focused on enhancing the quality of life and survival rates for men diagnosed with prostate cancer, the company is dedicated to conducting rigorous clinical trials to validate its groundbreaking therapies.